Qube Research & Technologies (QRT)’s AbCellera Biologics ABCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$600K Buy
+41,126
New +$390K ﹤0.01% 2841
2026
Q1
– Sell
-122,592
Closed -$419K – 3482
2025
Q4
$419K Buy
+122,592
New +$547K ﹤0.01% 2854
2023
Q4
– Sell
-26,967
Closed -$124K – 4297
2023
Q3
$124K Buy
+26,967
New +$164K ﹤0.01% 2583
2023
Q2
– Sell
-95,621
Closed -$721K – 2335
2023
Q1
$721K Sell
95,621
-162,896
-63% -$1.48M ﹤0.01% 1421
2022
Q4
$2.62M Buy
258,517
+206,750
+399% +$2.39M 0.01% 857
2022
Q3
$512K Buy
+51,767
New +$568K ﹤0.01% 1456
2022
Q2
– Sell
-149,417
Closed -$1.46M – 2429
2022
Q1
$1.46M Buy
149,417
+129,744
+660% +$1.23M 0.01% 969
2021
Q4
$281K Buy
+19,673
New +$299K ﹤0.01% 1831

Other funds holding ABCL

Qube Research & Technologies (QRT)'s ABCL Position: Q3 2026 in Review

Qube Research & Technologies (QRT) opened a new position in AbCellera Biologics (ABCL) in Q3 2026: 41,126 shares worth $600K. The stake represents ﹤0.01% of the portfolio and ranks #2841 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in ABCL as recently as Q4 2025.

Qube Research & Technologies (QRT) first reported a position in ABCL in Q4 2021 and has held it in 8 quarters since. The position peaked at $2.62M in Q4 2022. 164 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Qube Research & Technologies (QRT) held 41,126 shares of AbCellera Biologics worth $600K as of Q3 2026.
  • AbCellera Biologics was a new Qube Research & Technologies (QRT) position in Q3 2026.
  • AbCellera Biologics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #2841 holding.
  • Qube Research & Technologies (QRT) first reported a position in AbCellera Biologics in Q4 2021 and has held it in 8 quarters since.
  • Qube Research & Technologies (QRT)'s AbCellera Biologics position peaked at $2.62M in Q4 2022.
  • 164 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.